Gene-Enhanced Stem Cell Reprogramming for Age-Related Functional Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The aging process leads to functional losses in stem cells and somatic cells, including sarcopenia, cognitive impairment, dementia, immunosenescence, and loss of cellular and general body energy production, resulting in decreased quality of life and health span, and increased healthcare costs.
Innovation Solution
A multi-step process involving the mobilization, cryopreservation, and reprogramming of adult stem cells using gene vectors and exosomes to restore youthful methylation and acetylation patterns, enhance specific genes (like klotho, follistatin, hTERT, PGC1-alpha), and deliver them systemically or locally to rejuvenate cellular functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are used for regenerative therapy, then cellular function restoration is improved, but the effectiveness is limited by age-related functional losses
Solution Approach 1:
The patent applies parameter changes by modifying epigenetic parameters (methylation and acetylation patterns) of stem cells to restore youthful gene expression profiles. This resolves the contradiction by changing the biochemical parameters of aged stem cells, enabling them to regain regenerative capacity despite age-related functional losses.
Solution Approach 2:
The patent uses gene vectors as intermediaries to deliver therapeutic genes into stem cells. These vectors mediate the transfer of genetic material that enhances stem cell function and reverses age-related declines, thereby improving regenerative effectiveness without requiring the stem cells to naturally overcome aging limitations.
2Reliability
If gene therapy is applied to enhance stem cell function, then regenerative potential is improved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent merges gene therapy with stem cell therapy into a single integrated treatment approach. By combining these two therapies, the protocol enhances stem cell regenerative potential while managing complexity through a unified multi-step process that coordinates gene delivery, stem cell isolation, reprogramming, and reinfusion in a systematic manner.
Solution Approach 2:
The patent segments the complex treatment into distinct phases: gene vector preparation, stem cell isolation and culture, epigenetic reprogramming, and reinfusion. This segmentation makes the overall complex protocol more manageable by breaking it into discrete, optimized steps that can be performed sequentially with specialized protocols for each stage.
3Manufacturing precision
If multiple reprogramming methods are used to restore epigenetic patterns, then cellular rejuvenation is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs continuous epigenetic reprogramming through multiple complementary methods (methylation modification and acetylation modification) that work simultaneously or sequentially to progressively restore youthful epigenetic patterns. This continuous action ensures thorough reprogramming accuracy while managing complexity through a coordinated multi-method approach rather than discrete separate procedures.
Data Source
AI summary
Using adults stem cells (ASC) including hematopoietic cell (HSC), endothelial progenitor cells and mesenchymal (MSC) stem cells; mobilizing ASC cells into the vascular system using a collection system of one of: (i) an apheresis. (ii) bone marrow; or (iii) direct collection of ASC from the peripheral blood; providing the ASC with a cryopreservation conservation container of about minus 80 degrees centigrade collecting the ASC for defrosting and placed in a sterile container; reprogramming stem cells (RSC) including at least one of (i) RSC by methylation patterns of DNA such as JMJD3 and HDAC; (ii) RSC by acetylation patterns of DNA such as HDAC; (iii) epigenetic programming with a protein of interest (ncRNA); using vectors of AAV or CMV to transfer to specific genes to provide proteins to enlarge physical conditions to lost during the aging process.